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                                   INTRODUCTION 
 
Globally the medical fraternity is facing a major challenge in the form of 
increasing incidence of colorectal carcinoma. Colorectal cancer is the 3rd most 
common malignancy reported worldwide. Countries like North America, Australia, 
and Europe are facing an increased incidence of colorectal carcinoma.  [1] When 
compared to the western world, colonic cancer is less common in India. [2] 
Colorectal carcinomas are mostly associated with diet, genetics and environmental 
factors. With westernization of life style, India is facing an increase in incidence of 
colorectal cancer. [1] 
Two different pathogenetic pathways are implicated in colorectal carcinomas. The 
microsatellite stable pathway (MSS) where there is inactivation of tumor 
suppressor genes like APC, p53, and DCC. The other pathway which plays a major 
role in colorectal carcinomas is inactivation of mismatch repair genes such as   
MLH1, MSH2, MSH6, PMS2, and MSH3. These belong to microsatellite 
instability pathway (MSI).  
Literature states that virtually all the cases of Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC) / Lynch syndrome and 15% of sporadic cases of colorectal 
carcinomas have MSI. Mutation in two MMR genes, MLH1 and MSH2 accounts 
for majority of cases of HNPCC [1] 
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It is postulated that testing for MSI would serve two purposes: 
1. It is a powerful tool to screen for HNPCC and therefore members of the family 
with HNPCC can benefit from clinical survey by colonoscopy.  
2. Though MSI colorectal carcinomas are relatively insensitive to treatment with 5- 
flurouracil based chemotherapy, they have a better prognosis. [1] 
 
Hence the knowledge of the MSI status in colorectal carcinoma cases would help 
the clinician to assess the prognosis and also to guide in therapy. 
 
MMR deficient sporadic and hereditary colorectal carcinomas are frequently 
located in the ascending colon. These are large tumors and are usually of high 
grade. They also have peritumoral and intratumoral lymphocytic infiltrate which 
are implicated for better prognosis.  
Though molecular testing is gold standard for MSI testing to diagnose mismatch 
repair gene defects there are several studies which suggest a >95% specificity for 
immunohistochemical analysis.  
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Molecular testing for MSI is laborious, time consuming, expensive and can be 
done only in selected  diagnostic laboratories, whereas immunohistochemical 
method costs 14-28% less, less time consuming and can be done in any pathology 
laboratory. 
 
Therefore we propose to study the deficiency of MMR protein expression by 
immunohistochemical method in a series of colorectal carcinoma cases reported 
from our institute and to correlate with various clinicopathological characteristics.  
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AIMS AND OBJECTIVES 
 
1]  To determine the frequency of loss of mismatch repair protein (MLH1 and      
MSH2) expression by immunohistochemical method in colorectal carcinomas. 
 
2] To study its correlation with various clinical and histopathological 
characteristics and to determine if there is any significant association  between the 
two. 
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                              REVIEW OF LITERATURE 
 
Carcinoma  of the colon is  the third most common cancer and it accounts for 8.5% 
of cancers worldwide in 2000. About 945,000 new cases of colorectal carcinomas 
are being diagnosed every year. As per the statistical data by US Surveillance 
Epidemiology and End Results (SEER), the incidence of colonic carcinoma is 33.7 
per 100,000 and that of rectal carcinoma is 12.8 per 100000. Both are common 
among males. [1] Incidence rate of colorectal carcinoma in Asia varies widely.  It is 
uniformly low in all South Asian countries and high in developed Asian countries 
like Japan, South Korea and Singapore. [2] 
In India the incidence rate is low and it represents about 2% of all the 
malignancies. Rectal carcinoma is more common when compared to colon cancer 
in India. Rural population based studies show very low incidence rate of colon 
carcinomas and high incidence rate of rectal carcinomas probably due to limited 
data collection.[3] Some population based studies show that there is a rising trend in 
the incidence of colorectal carcinoma in India.[4]  
Colonic carcinomas occur most commonly in elderly men and the risk of acquiring 
colorectal carcinoma increases with age after 40 years of age. Family history also 
plays an important role in the etiology. Colorectal cancers may be sporadic or 
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familial. Sporadic cases have a multifactorial etiology such as dietary habits- 
western type diet, sedentary life style, long standing inflammatory bowel disease, 
pelvic irradiation. [1] 
High intake of red meat can increase the risk of colorectal cancers, probably due to 
increased production of heterocyclic amines, stimulation of higher levels of fecal 
bile acids, increased production of  oxygen free radicals and increased insulin 
levels. On the other hand intake of high vegetable and fiber diet prevents colorectal 
cancer. [1] Incidence of colorectal carcinoma among Indian immigrants in United 
States and United Kingdom is found to be high, suggesting a causal relationship 
with life styles and dietary habits. [4] 
At least two distinct genetic pathways have been described in the development of 
familial colorectal cancers.  
1. APC/β- catenin pathway associated with classic adenoma – carcinoma sequence. 
2. Microsatellite instability (MSI) pathway with defects in DNA mismatch repair 
genes (MLH1, MSH2, MSH3, PMS2 and MSH6).   
Mutation of APC gene causes Familial adenomatous polyposis.  MSI is present in 
virtually all the cases of hereditary nonpolyposis colorectal cancer (HNPCC) and 
approximately 15% of sporadic cases. Mutation in two MMR genes, MLH1 and 
MSH2 accounts for majority of cases of HNPCC [5] 
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The presence of colorectal cancer in a first degree relative increases a person’s 
lifetime risk for developing colorectal cancer from 1.8 –fold to as high as eightfold 
that of general population. The incidence of colonic neoplasm among first degree 
relatives of colorectal cancer patients ranges from 15% to 20%.The risk will be 
increased  in those having more than one affected relative. This kind of familial 
clustering of colorectal cancer could be due to shared gene pool, a shared 
environment or a combination of both. [6] 
  
Apart from dietary and genetic factors, other factors associated with colorectal 
carcinomas include diverticulosis, inflammatory bowel disease, socioeconomic 
factors, hormonal factors, radiation, gall stones & cholecystectomy. [7] 
It was Burkitt who suggested the coexistence of diverticulosis and colorectal 
cancers and is more frequently observed among western population compared to 
Asian. Patients with inflammatory bowel disease exhibit an increased risk of 
developing colorectal carcinoma.[8] The incidence of colorectal carcinoma is 4 to 
20 times greater in patients with inflammatory bowel diseases when compared to 
normal population. They also develop cancer outside of the GI tract. Several 
studies have shown an increased incidence of right sided colonic cancer in women 
of all ages and a relation with parity, which may protect against the development of 
colorectal cancer.  It has also been found that 70% of colonic cancers are estrogen 
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receptor positive. [9]   Women radiated for gynaecological malignancies have a 
relative high risk for subsequent colonic cancer of 2.0 to 3.6 times. [10] 
 
 
The  WHO  sub classifies colorectal carcinoma as follows: 
• Adenocarcinoma 
• Mucinous adenicarcinoma 
• Signet ring cell adenocarcinoma 
• Small cell carcinoma 
• Squamous cell carcinoma 
• Adenosquamous carcinoma 
• Medullary carcinoma 
• Undifferentiated carcinoma 
Most colorectal carcinomas are located in sigmoid colon and rectum.  Recent  
trends show an increased incidence of  proximal carcinomas. Tumors with high 
levels of microsatellite instability are more frequently located in cecum, ascending 
colon and transverse colon. [11] 
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The gross appearance of colorectal carcinomas may be polypoid, fungating 
(exophytic), ulcerating, stenosing or diffusely infiltrating. Generally in caecum 
they are bulky, exophytic and polypoidal, rarely causing obstruction, whereas the 
proximal colorectal carcinomas are most often infiltrative and ulcerating producing 
annular constricting tumors.  
CONVENTIONAL ADENOCARCINOMA: 
The diagnostic feature of colonic adenocarcinoma is the invasion through 
muscularis mucosae into sub mucosa. If the tumors have high grade morphological 
changes but fail to invade muscularis mucosa, the term intramucosal neoplasia is 
used.  [11] 
Most carcinomas have atypical cells arranged in glandular pattern with 
morphology ranging from well to moderately differentiated. Histological grading is 
mainly based on the architecture. 
 Well differentiated adenocarcinoma  (grade 1) exhibit glandular structures in 
>95% of tumor 
 Moderately differentiated adenocarcinoma (grade2) has 50-95% 
    glandular structures 
 Poorly differentiated (grade 3) adenocarcinomas have 5-50% glandular 
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structures. In poorly differentiated tumors, cells are predominantly arranged 
in solid sheets and the cells exhibit loss of nuclear polarity and considerable 
nuclear pleomorphism. 
 Undifferentiated grade (grade 4) has <5% glandular structures. When one 
portion of the tumor appears well differentiated while other area is poorly 
differentiated, the histological grade is assigned according to the least 
differentiated area found.[ 12] 
 
MUCINOUS ADENOCARCINOMA: 
When more than 50% of the tumor is mucinous, it is classified as mucinous 
adenocarcinoma. About 10 to 15% of colorectal carcinomas and 33% of rectal 
carcinomas are mucinous tumors. Histologically it is characterized by pools of 
extracellular mucin in which tumor cells are floating as acini or as single cells. 
This type has an association with high frequency microsatellite instability and 
often affects young patients. Mucinous carcinomas have a poor prognosis probably 
due to delay in diagnosis. These tumors show more extensive lymphnode 
involvement and are likely to invade adjacent viscera when compared to non 
mucinous adenocarcinomas. [12] 
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SIGNET RING CELL CARCINOMA: 
This is a variant of mucinous adenocarcinoma characterized by the presence of 
signet ring cells (cells with abundant intracellular mucin pushing the nucleus to the 
periphery) in > 50% of the tumor. They represent about 0.5 to 1.0% of all 
colorectal carcinomas and usually occur in younger age group. Like mucinous 
adenocarcinoma, signet ring carcinoma also present at an advanced stage and has a 
poor outcome. [13] Some MSI tumors are of this type. 
SQUAMOUS CELL CARCINOMA 
Primary squamous cell carcinomas of colon are very rare. There are different 
theories about its histogenesis, many favour an origin from pluripotent stem cell. 
Other theory suggests its origin from metaplastic foci associated with chronic 
inflammation. [14 ] Microscopically it resembles squamous cell carcinoma of any 
other organ. Diagnosis of squamous cell carcinoma can be made only after 
excluding secondary metastasis from other sites. 
 ADENOSQUAMOUS CARCINOMA: 
These are extremely rare neoplasm accounts for 0.06% of all colorectal cancers. 
Histologically it show features of both squamous and adenocarcinoma. Both these 
components can be seen either as separate components or admixed [1]  
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MEDULLARY CARCINOMA: 
Medullary carcinoma  is a recent entity recognized by WHO. Microscopically, it is 
composed of sheets of large polygonal cells having vesicular nuclei, prominent 
nucleoli and abundant eosinophilic cytoplasm. It is often associated with a dense 
lymphocytic infiltrate. It was first described by Jessurrun and coworkers as an 
undifferentiated carcinoma. These tumors are more likely to harbor mutations in 
KRAS and TP53 and defects in DNA mismatch repair gene. These tumors are 
common in women and occur in proximal colon.  Medullary carcinomas have a 
more favorable prognosis. [15] 
 
UNDIFFERENTIATED CARCINOMA: 
They have variable morphology and lacks differentiation beyond their epithelial 
origin. These tumors are usually seen in association with MSI and have a poor 
prognosis. [11] 
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OTHER VARIANTS 
CARCINOSARCOMA 
Malignant tumors containing both carcinomatous and heterologous mesenchymal 
elements are termed as carcinosarcoma.  
Other rare variants include choriocarcinoma, giant cell carcinoma, clear cell 
carcinoma, stem cell carcinoma and paneth cell- rich carcinoma [11] 
                Staging of colorectal carcinomas 
Dukes’ staging:[12] 
This staging was proposed by dukes in 1937. By this staging the colorectal 
carcinomas are staged by the level of infiltration of the wall by the tumor as; 
Stage A:  Tumor confined to the bowel wall 
Stage B:  Tumor infiltrating  the serosa or the perimuscular fat   in  areas without 
peritoneal covering. 
Stage 3: Tumors with lymph node metastases 
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Astler and coller staging: [12] 
This staging was proposed in the year 1957. 
Stage A: Tumor confined to mucosa. 
Stage B1: Tumor involving the muscularis propria  without penetrating it. 
Stage B2: Tumor penetrating muscularis propria 
Stage C1: Tumor limited to bowel wall with lymph node metastases 
Stage C2: Tumor penetrating the bowel wall and featuring lymph node metastases. 
Now the currently used staging was the one proposed by World Health 
Organisation , taking into consideration of  three factors such as the details of 
primary tumor with level of infiltration ( T ) , lymph node metastases( N)  and 
presence of distant metastases (M). This staging is known as TNM staging. 
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 TNM STAGING OF COLORECTAL CARCINOMA [11] 
T- primary tumor 
TX-primary tumor cannot be assessed  
T0- No evidence of primary tumor 
Tis- Carcinoma in situ; intraepithelial neoplasia or invasion into lamina propria 
T1 –Tumor invades submucosa 
T2-Tumor invades muscularis propria 
T3- Tumor invades through muscularis propria into subserosa or into non 
peritonealised pericolic or perirectal tissues 
T4-Tumor directly invades other organs or structures and/or perforates visceral 
peritoneum. 
N – regional Lymphnodes 
NX – Regional lymphnodes cannot be assessed 
N0- No regional lymph node metastases 
N1- Metastases in 1 to 3 regional lymphnodes 
N2- metastases in 4 or more regional lymphnodes 
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 M- Distant metastases 
 MX- Distant metastass cannot be assessed 
 M0- No distant metastases 
M1- Distant metastases 
Stage grouping: 
Stage 0 Tis N0 M0 
Stage I T1 
T2 
N0 
N0 
M0 
M0 
Stage II T3 
T4 
N0 
N0 
Mo 
M0 
Stage III Any T 
Any T 
N1 
N2 
M0 
M0 
Stage IV Any T Any N M1 
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CLINICAL FEATURES: 
 About 5% to 12.5% of the patients are asymptomatic. [16] 
The clinical symptoms depends on tumor location( right or left), stage of the 
disease (early or late). 
 Weight loss and malaise may be the first symptoms which are often ignored 
by the patient. 
  The right sided lesions, say tumour in the right side of colon are usually flat 
or polypoidal and rarely cause obstruction. These lesions remain clinically 
silent for a long period of time.  
 Occult or massive rectal bleeding: occult bleeding diagnosed as an incidental 
finding in the stool serves as an indicator of colorectal carcinomas. Bleeding 
may be so severe to cause iron deficiency anemia thereby causing weight 
loss and malaise. 10.3% of patients with clinical history of rectal bleeding 
are found to have proven colon cancer.[17] 
 In rare cases the patients presents with cardiac failure due to anemia.[17] 
 Altered bowel habits:  
• Seen in 22% to 58% of patients. 
•  Prevalent in left sided lesions. 
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• The changes are minimal at the early stages and as the tumor increases 
in size and encircles the entire colonic wall it causes constipation, 
obstipation and a sense of incomplete rectal emptying. 
 Abdominal pain is the presenting symptom in some of the cases. The pain 
mostly occurs in cancers invading the serosa and adjacent structures. Rarely 
large masses, completely obstructing the lumen also cause pain. Lower 
abdominal pain mostly occurs in patients with caecal or ascending colon 
lesions. The tumors of ileocaecal valve causes obstruction of appendiceal 
lumen causing appendicitis..[18] 
TUMOR MARKERS: 
 These are the diagnostic biomarkers that helps in identification of recurrent 
disease: 
                                1] Carcinoembryonic antigen (CEA) 
                                2] Cytokeratins 
                                3] Tumor M2-PK 
                                4] Circulating nucleic acids 
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1] The well known soluble diagnostic biomarker of colorectal carcinomas is 
‘CARCINOEMBRYONIC ANTIGEN’, shortly called CEA. This antigen serves as 
a cell adhesion molecule in early fetal life, the production of which ceases in adult 
hood. An increased level of CEA is noted in healthy smokers and also in many 
benign and malignant conditions. The benign lesions include pancreatitis, liver 
cirrhosis, ulcerative colitis, diabetes mellitus type 1 and type 2. The various 
malignant lesions showing increased levels of CEA are colorectal cancer, gastric 
cancer, pancreatic cancer, lung cancer and breast cancer. [19] 
2] The potent rival of CEA in predicting recurrence of colorectal carcinomas is 
circulating cytokeratins. In a study done by Fernandez and his colleagues it was 
found to be better than CEA. They examined 120 colorectal carcinoma patients, 
and an elevated cytokeratin level was found in 48% of them with recurrent disease 
whereas CEA was increased in only 30% of recurrence cases.[20] 
3]  Tumour M2-PK: 
This is an enzymatic marker that can be identified in the stool. This is a dimeric 
form of the glycolytic pyruvate kinase isoenzyme. There is an upregulation of this 
enzyme in all proliferating cells. This test has a sensitivity of 91% and specificity 
of 79% respectively. [21] 
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4] Circulating Nucleic acids: 
Circulating tumor DNA and mRNA in blood of patients with colorectal cancer 
serves as a marker for recurrence. In a study by Deihl . F  it was concluded that 
circulating levels of detectable tumor DNA in patients’ blood during the first post 
operative visit accurately predicted the recurrence of  tumor in the future.[22] 
 MOLECULAR  GENETICS  OF  COLORECTAL  CARCINOMA  
 
Colorectal carcinomas can be hereditary or sporadic. Lynch and Lynch in 1998 
published a classification of hereditary disorders predisposing to colorectal 
carcinomas. They have not only classified the different cancer syndrome but also 
explained their pattern of inheritance and associated gene mutation, polyp 
information, other non-cancerous characteristic of the syndrome. [23] 
According to them the predisposing syndromes are:  
• Familial adenomatous polyposis 
• Attenuated familial adenomatous polyposis 
• 11307 K mutation in Ashkenazi Jews 
• Juvenile polyposis coli 
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• Hereditary adenomatous polyposis 
• Peutz – Jeghers  syndrome 
• Familial adenomatous polyposis 
• Familial ulcerative colitis and Crohn’s disease. 
Most of them are autosomal dominant except Familial colorectal cancer , Familial 
ulcerative colitis and Crohn’s disease.  
Hereditary cancer syndromes are broadly divided into Polyposis and Non 
polyposis syndromes. Polyposis syndromes includes adenomatous and 
hamartomatous polyposis. Non polyposis syndromes include lynch syndrome, 
Muir – Torre syndrome and Turcot syndrome.  
 
HAMARTOMATOUS POLYPOSIS SYNDROME 
Hamartomatous polyposis syndrome includes Peutz – Jeghers polyps and Juvenile 
polyposis. 
PEUTZ –JEGHERS POLYPOSIS: 
These hamartomatous polyps are characteristically seen in stomach, small intestine 
and colon. They are architecturally different resembling a branching tree due to the 
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infiltration of muscularis mucosa into the mucosa of the polyp. The patients have 
pigmentation in the lips and oral cavity. This is due to the mutation in the gene 
coding for serine- threonine kinase on chromosome 19p13.3. [24] 
 
 
JUVENILE POLYPOSIS: 
Most commonly it occurs in children and is characterised by diffuse presence of 10 
or more hamartomatous polyps throughout the gastrointestinal tract. Mostly they 
are benign and have mutation in the gene coding for tyrosine –phosphate protein. 
(PTEN) [23] 
 
ADENOMATOUS POLYPOSIS SYNDROME 
The adenomatous polyposis syndrome includes Familial Adenomatous Polyposis 
and Attenuated Familial Polyposis Syndromes. 
FAMILIAL ADENOMATOUS POLYPOSIS 
Familial adenomatous polyposis is an autosomal dominant disorder characterised 
by the presence of numerous colorectal adenomas during their teens. Atleast 100 
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polyps are neccassary for a diagnosis of classic Familial Adenomatous Polyposis. 
Sometimes thousands of polyps can be present. It is caused by the germ line 
mutation of adenomatous polyposis coli (APC) gene .  
Individuals who are born with one mutant APC gene develop Familial 
adenomatous polyposis and invariably one or more of these polyps undergo 
malignant transformation resulting in colorectal carcinoma. APC gene is a tumour 
suppressor gene, so both copies of it must be lost for a tumour to develop.  
Adenomatous polyposis coli gene (APC) is located in chromosome 5q21-22. This 
is a 120 kb gene with 21 exons in which 7 are alternatively expressed. The main 
function of this gene is to down regulate the growth promoting signals. APC gene 
shows high expression in CNS, although found in all other tissues. The product of 
APC gene, ‘APC protein’ is a negative regulator of Wnt signalling pathway. There 
are several domains in the gene that acts as binding and degradation sites for beta 
catenin, among which the one at the carboxy terminal end by mediating the 
phosphorylation of GSK3b forms a stabilising complex between GSK3b and APC. 
This in turn mediates phosphorylation of conduct / axin that recruits beta catenin 
and targeting its degradation through APC dependent ubiquitin – proteasome 
pathway. 
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Normally Wnt signalling releases beta catenin from its inhibitory complex (GSK3b 
– axin), causing its accumulation in the cytoplasm. Beta catenin in the cytoplasm 
binds to microtubules and also interacts with E-cadherin (cell adhesion potein). 
Rest of the free beta catenin moves to the nucleus and binds to TCF/LEF 
transcription factor family activating c-myc oncogene and cyclin D1 protein , 
whose uncontrolled activation in the absence of APC gene regulation culminates in 
carcinogenesis.  
Other genetic mutations associated are TP 53, loss of 17p, 18 and 22 alleles. Also 
k-ras mutation causes cyclin D1 transcription and promotes carcinogenesis. [25] 
Colonic cancer develop in 100% of untreated FAP patients before the age of 30 
years; hence a prophylactic colectomy is the standard therapy for individuals with 
APC gene mutation. [26] 
FAP is also associated with other extra – intestinal manifestations like 
development of Gardner syndrome and Turcot syndrome. Gardner syndrome is 
characterised by multiple adenomas, osteomas, epidermal cyst, desmoid tumors, 
thyroid tumors and dental abnormalities. Turcot syndrome is characterised by 
intestinal adenoma and tumors of central nervous system like meduloblastoma and 
glioblastoma. [26] 
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ATTENUATED FAMILIAL POLYPOSIS SYNDROMES 
Interestingly correlations have been observed between the location of APC gene 
mutation and the phenotype.  Attenuated APC (AAPC) occurs when there is 
mutation in the first and last third part of the gene. It is characterised by late onset 
with less than 100 polyps and have a prevalence for fundic gland polyps. When 
mutation occurs in the central region, in the codon1309 – there is a severe 
phenotype characterised by about 1000 polyps at young age, whereas mutation at 
codon 386 or 1465 only mildly interferes with APC gene function. [27] 
 
 
 LYNCH  SYNDROME:  
Also called hereditary non polyposis colorectal cancer [HNPCC] is an autosomal 
dominant condition and is characterised the increased risk of colorectal cancer 
along with carcinomas of endometrium, ovary, stomach, urinary tract and 
glioblastoma multiforme of brain. Lynch patients have an early onset of right sided 
colorectal carcinoma and is associated with synchronous and metachronous 
cancers. Amsterdam criteria (Table 1) were established in 1991 for the diagnosis of 
lynch syndrome. [28] 
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TABLE 1               AMSTERDAM CRITERIA 1991  
Three or more relatives with colorectal cancer plus all of the following 
• One affected person is a first-degree relative of the other two affected     
  persons 
• At least two successive generations should be affected 
• At least one cancer should be diagnosed before age 50 
 
 
 Later Amsterdam criteria 1 were revised in 1999.  Table 2 shows revised 
Amsterdam II criteria [29] 
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TABLE 2  
Amsterdam II criteria (Revised International collaborative Group on Hereditary 
Non-Polyposis Colorectal Cancer (HNPCC) Criteria 1999  
There should be at least three relatives with colorectal cancer or with a lynch 
syndrome associated cancer plus all of the following 
• One relative should be a first degree relative of the other two 
• Atleast two successive generations should be affected 
• Atleast one tumor should be diagnosed before the age of 50 yrs 
• FAP should be excluded in CRC case if any 
• Tumors should be verified by histopathological examination. 
 
 
Genes that underlie HNPCC are the mismatch repair genes that includes MLH1, 
MSH2, MSH6 and PMS2. The function of these genes is to correct the base –base 
mismatches that occur during DNA replication, failure of this leads to insertion or 
deletion of short repetitive sequences in the DNA coding regions causing 
microsatellite instability. [30] 
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Muir –torre syndrome: 
A type of Lynch Syndrome with sebaceous tumours and are caused mainly by 
MSH2 mutation. [26] 
 
Turcot syndrome: 
This syndrome is characterised by the presence of medulloblastoma , glioblastoma, 
colorectal cancers and rarely polyposis . Patients with medulloblastoma has APC 
gene defect and those with glioblastoma has primarily PMS 2and MLH1 defect [26] 
About 90% of colorectal carcinomas associated with HNPCC show microsatellite 
instability with predominant mutation in either MLH1 or MSH2 or both. [31] 
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GENETIC  PATHWAYS OF COLORECTAL CANCER 
 The various genetic pathways leading to colorectal carcinomas include; [32]                      
                1) Adenoma – Carcinoma sequence 
                2) Serrated neoplasia pathway 
                3) Microsatellite instability pathway and mutation of MMR genes.   
Adenoma – Carcinoma sequence 
This pathway is also called suppressor pathway due to the inactivation of tumor 
suppressor genes in the carcinogenesis. The various genes involved are APC, 
TP53, SMAD4 located on chromosomes 5q, 17p and 18q respectively. 
Activation of k-ras oncogene and deletion of DCC [deleted in colorectal cancer] 
located on 18q are other proposed alterations in this pathway. 
 
Serrated neoplasia pathway: 
Hyperplastic polyps progress to serrated adenoma and later to carcinoma. These 
tumors have a serrated epithelial lining. Tatayema et al proposed that the molecular 
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basis of these tumors may be the decreased expression of CD 95 of apoptosis. 
About 15% show defect in Wnt signaling pathway. Other mechanisms suggested 
are BRAF and K-ras mutation.  [33] 
 
Microsatellite instability and MMR pathway: 
The  hall mark of  HNPCC is microsatellite instability. Microsatellites are simple 
repetitive DNA sequences in a genome and are composed of one or more base pair 
units that may be repeated several times. During DNA replication, errors can occur 
in their repetitive subunits resulting in contraction or elongation of a microsatellite 
sequence, a process described as microsatellite instability (MSI).  This is important 
when MSI are in the critical areas of the gene responsible for cell growth 
regulation. Mismatch repair genes play a crucial role in detecting and correcting 
these types of errors. Failure to correct these errors due to defect in mismatch 
repair genes can lead to frame shift mutations with loss of normal function of these 
genes and development of tumour. [34] 
There are several mismatch repair genes. The most important genes include MSH2 
(Mut S homologue 2), MSH6 (Mut S homologue 6), MLH1 (Mut L homologue 1), 
MSH3 ( Mut S homologue 3) and PMS2 (Postmeiotic segregation 2). The MSH2 
protein recognises and binds to the mismatched sequence. If a single base pair 
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mismatch is recognised it forms a heterodimeric complex with MSH6 and if there 
is a larger 2 to 8 nucleotide insertion or deletion it combines with MSH3. A second 
heterodimeric complex of MLH1 and PMS2 is recruited which subsequently 
directs the remaining set of genes to excise the mismatched nucleotide. [35] 
MMR genes are expressed in all adult tissues but are most prominent in the 
epithelium of gastrointestinal tract, testis, ovary and is highly expressed in the 
replication zone. 
MSI is seen in nearly all tumours of HNPCC and about 15% of sporadic cancers. 
HNPCC is transmitted as an autosomal dominant trait and shows germline 
mutation in one or more of the mismatch repair genes. Mutations of MLH1 and 
MSH2 are more common and they occur in exon 16 and exon 12 of the genes 
respectively. [36] Another 12% of colorectal carcinomas represent non-inherited 
form of DNA mismatch repair gene inactivation due to methylation of the 
promoter of the MLH1 gene, which can cause defect in its function.[37] 
MSI- tumors, mostly arises in the right side colon which has a poorly differentiated 
mucinous phenotype and a female preponderance , but it has a good prognosis.  
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     METHODS OF TESTING MICROSATELLITE INSTABILITY 
 
Microsatellite instability is due to insertions or deletions of sequences in short 
tandem repetitive sequences in DNA. The only method for identifying these 
sequences is by PCR amplification of the tumour DNA with the five markers 
recommended by National Cancer Institute conference on MSI. 
MSI testing: 
MSI testing was first performed by Peltomaki et al who was the first to document 
the genetic basis of HNPCC. [38] 
Extraction of DNA: 
To do a MSI analysis, DNA is obtained from the tumour and adjacent normal 
tissues by proteinase K digestion, followed by phenol/chloroform extraction and 
ethanol precipitation. 
Selection of markers: 
A standard panel consisting of 5 microsatellite markers as suggested by National 
Cancer Institute is used. This includes BAT26, BAT40, D2S123, D5S346 and 
D17S250. These are used as primers for the subsequent PCR reaction. 
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 The reaction mixture consisting of template DNA, Taq  polymerase and the 
primers are subjected to 35 cycles of PCR. [39] 
The PCR products then undergo PAGE electrophoresis. The alterations in 
microsatellites are detected by changes in the length of DNA strands when 
compared to adjacent normal tissue. MSI is scored by the occurrence of novel 
bands in the tumour DNA or similar shift in all bands with a retained normal band 
pattern.[40] 
Based on the electrophoresis pattern, the instability is categorised as follows:[40] 
MSI-H (high) – If 2 or more markers showed instability. 
MSI-L (low) - If only one marker showed instability. 
MSS- When there are no alterations in any of the marker. 
In another study by Maingold et al [41], when there is instability in only one of the 
marker, an additional panel of 5 markers namely BAT 40, D10S197, D13S153, 
MYCL1 and D18S58 were subjected to PCR with these tissues and the results are 
graded as: 
MSI-L – Instability in one or two of the total 10 markers.  
MSI-H – Instability in 3 or more of the total 10 markers  
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Microsatellite instability, though a signature feature of lynch syndrome is also seen 
in 15% of sporadic colorectal carcinomas. The microsatellite instability in these 
cases is mostly caused by methylation induced silencing of MLH1 gene.MSI-L 
tumours do not show the characteristic histopathological features of MSI-H 
tumours and they are not associated with germ line mutations in MMR genes. 
These cases are due to non mutational down regulation of MSH-3. [42] These 
individuals were selected for MSI testing based on Amsterdam criteria. Now the 
recently used criteria is revised Bethesda guidelines: [43]   
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TABLE 3 
1. Patient diagnosed as colorectal cancer before the age of 50 years 
2. Presence of synchronous or metachronous colorectal or other HNPCC related 
tumors  ( stomach, urinary bladder, ureter and renal pelvis, biliary tract, 
brain(glioblastomas), sebaceous gland adenomas, keratoacanthomas and small 
bowel cancer, regardless of age. 
3. colorectal cancer diagnosed before 60 years of age with morphology suggestive of 
MSI-H ( including the presence of tumor infiltrating lymphocytes, Crohn – like 
lymphocytic reaction, mucinous or signet ring cell differentiation, or medullary 
growth pattern). 
4. CRC in a patient with 1 or more first degree relatives with CRC or other  HNPCC 
related tumors( one of  the cancers must be diagnosed before 50 years of age, and 
adenomas must be diagnosed before 40 years of age.) 
5. CRC in a patient with 2 or more relatives having CRC/other HNPCC related 
tumours, regardless of age. 
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 DETECTION  OF MISMATCH  REPAIR  GENE  MUTATIONS 
 As said earlier, loss of function of several mismatch repair genes such as MSH2, 
MLH1, PMS2 and MSH 6 plays a causal role in colorectal carcinomas particularly 
in those showing MSI-H instability. As MSI testing is labour intensive and 
cumbersome ways for detection of loss of MMR protein expression in tumour 
tissue came into existence. 
 The MMR protein expression can be identified by immunohistochemistry. [44] The 
principle behind this method is antigen antibody reaction. The blocks of resection 
specimen with the tumour tissue is taken and then 5 microns thick sections were 
cut and taken in a poly-l- lysine coated slide. Sections were incubated overnight at 
56 degree C. The slides are then dewaxed and dehydrated in graded alcohol. 
Rehydration is done finally with distilled water. Antigen retrieval is done in a 
specific method with a buffer followed by cooling in room temperature. After 
blocking endogenous peroxidise activity, they are treated with monoclonal 
antibody for 1 hour and secondary antibody is added followed by chromogen 
which imparts brown colour to the nucleus of the cells that had taken the primary 
and conjugated secondary antibody.  
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Mutations have been identified in all the 19 exons of MLH1 and 16 exons of 
MSH2. These genes also have variants based on the type of mutations or genetic 
alterations and are hence classified as follows: [45] 
1. Pathogenic mutation – generally frameshifts, nonsense and splice mutations 
2. Probable pathogenic mutation – nonconservative aminoacid changes. 
3. Probable polymorphisms – generally conservative changes, also observed in 
controls 
4. Definite polymorphism- synonymous variants. 
Mutations in these genes result in lack of expression of these proteins in the tissue 
which can be detected by immunohistochemical marker study using antibodies 
against these proteins. 
Apart from the immunohistochemical staining for MMRproteins, there are other 
means of detection of the mutations in these genes which includes: 
 Genomic sequencing 
 In vitro synthesised protein assay 
 DNA structure techniques. 
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     GENOMIC SEQUENCING: 
This is one of the most widely used methods in affluent centres. In this test all 
the 35 coding exons (16 exons of MSH 2 and 19 exons of MLH 1) are tested. 
The necessary DNA is amplified from peripheral blood leucocytes using a PCR 
reaction. PCR reaction is followed by an electrophoresis of end products.  
Yaping Wang [46] and his colleagues did genomic sequencing to look for large 
deletions in the two genes MLH1 and MSH2 based on multiplex PCR using 6 
pairs of primers encompassing both the genes. After a multiplex PCR, the 
analysis of end products was done using an agarose gel electrophoresis, 
visualised by ethidium bromide staining. As a result, in a total of 180 patients 
large deletions were seen in 19 cases.  
     IN VITRO SYNTHESISED PROTEIN ASSAY:  
In this technique an in vitro system is used where transcription and translation 
of a PCR product is done which is obtained from several exons of the MLH1 
and MSH2 genes. For this method mRNA is required for the production of 
cDNA . With this method several mutations such as frame shifts, splicing, out 
of frame deletions or insertions can be detected. [45] 
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    DNA STRUCTURE TECHNIQUES:  
These techniques are based on the structural changes in DNA molecule as a 
result of mutation. [45] 
The various techniques are: 
 Denaturing gradient gel electrophoresis 
 Single strand conformational polymorphism 
 Protein truncation test 
 Heteroduplex analysis 
 Two dimensional DNA typing 
Out of the above techniques Farrington et al [47] found that genomic sequencing had 
80% sensitivity compared to other techniques. 
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                                        NEED FOR MMR TESTING 
There is a need for the identification of loss of expression of mismatch repair 
proteins in the tumour due to various reasons. 
 MMR protein loss correlates with microsatellite instable tumours that too 
with those showing high grade of instability. [33] 
 MSI tumours are often associated with multiple synchronous and 
metachronous cancers that formed a basis for Bethesda criteria.  
Horri et al [48] found that there is 89% rate of MSI in 38 tumours having 
multiple malignancies. 
 Immunohistochemical pattern of MLH1 and MSH2 expression is observed 
to correlate with certain histopathological characters. 
In general microsatellite instability tumours have been associated with younger age 
at onset, more female incidence, increased involvement of proximal colon, large 
size, expanding pattern of growth, signet ring / mucinous / medullary morphology , 
peritumoral Crohn’s like lymphocytic response and intratumoral lymphocytic 
infiltration. [38] 
Giovanni Lanza [49]and his colleagues found that the immunohistochemical 
expression of MLH1 and MSH2 is significantly related to above histopathological 
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characters. In their study they evaluated immunohistochemical expression of 
MLH1 and MSH2 protein in 132cases of MSI and 150 microsatellite stable (MSS) 
colorectal adenocarcinomas. Loss of MLH1 or MSH2 expression was detected in 
120 cases of MSI carcinomas, whereas all MSS tumours showed normal 
expression of both proteins. They also reported that MSI-H tumors,which lacked 
the expression of MLH1/MSH2 showed significant correlation to various clinical 
and histopathological variables. The tumors with positive expression of MLH1 and 
MSH2 were conventional adenocarcinomas of well or moderately differentiated 
grade . Most of them were p53 positive, size less than 7cm in diameter and located 
in the distal colon. Whereas the tumors that lack these MMR proteins were mostly 
poorly differentiated and proximal in location. In addition, MLH1-negative 
carcinomas were less common among patients with Hereditary Non Polyposis 
Colorectal Cancer (HNPCC) or suspected HNPCC and in the group of patients 
aged <50 years. 
The clinical uses of MSI testing are: 
 Microsatellite instability testing helps us to classify familial cases of 
colorectal carcinomas. Valle and his colleagues [50] gathered families of 
colorectal cancers including both MSI and MSS. They found that MSI 
colorectal cancer families had a younger age of onset and proximal colon 
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distribution and about 60% of them are significantly linked to a mutation in 
DNA mismatch repair gene. 
 MSI cases have a survival advantage in spite of their poor differentiation in 
histology. This is attributed to intratumoral and peritumoral lymphocytic 
infiltration. Kriesten M.Drescher [51] and his men suggested that the defect in 
MMR proteins may be a reason for the increased lymphocytic infiltration. 
As a result of mutations in the MMR genes and deletions /insertions in the 
microsatellites, the tumour has a lot of altered proteins unique to itself. 
These new peptides are immunogenic and are recognised as foreign by the 
immune system. As a result there is infiltration by lymphocytes, particularly 
CD8+ T lymphocytes. 
 Another significant implication of loss of mismatch repair proteins is that 
these tumors are relatively insensitive to 5-flurouracil chemotherapy. Kim 
and his colleagues [52] stated that normally , DNA MMR system is 
responsible for signalling cell death when there is significant toxic DNA 
damage, whereas in these CRCs as there is loss of MMR genes function, 
these tumours are not susceptible to the damage caused by 5 fluorouracil, 
and are hence selectively resistant to 5FU based chemotherapeutic regimens. 
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 Vijay pandey and his co-men assessed mismatch repair protein expression 
in 46 patients with simultaneous detection of microsatellite instability using 
the five Bethesda markers. Assessment of microsatellite instability in 
colorectal carcinoma at an Indian center indicated that the incidence of MSI 
was similar to that of the west, despite lower incidence of colorectal cancers 
and predominance of rectosigmoid tumors in the Indian population. [39]  
 
Mariann christensen [40] and his colleagues compared IHC, MSI analysis and 
genomic sequencing of MLH1 and MSH2 genes in colorectal carcinomas, in 
patients either strictly meeting Amsterdam criteria or are suspected to be a HNPCC 
family. They concluded that IHC is comparatively more cost effective and can be 
used as a first screening test for detecting HNPCC families. 
 
 
 
 
 
 
44 
 
    MATERIALS AND METHODS 
          The cases diagnosed as colorectal carcinomas from colonic resection 
specimens during the period 2008 to 2011 in the department of pathology, 
PSGIMSR were included in the study. The case selection was done by systematic 
random sampling. The colonoscopic biopsy specimens were rejected from the 
study. 
           The clinical details like age, sex of the patients and other gross findings 
necessary such as site, size of the tumor were taken from the requisition slips. The 
representative paraffin blocks and H&E slides were retrieved from the archives of 
pathology. Paraffin blocks of the slides with high tumor density were chosen for 
the study.  4µ thick sections were made from the chosen blocks for routine 
hematoxylin and eosin staining. Then the cases were screened for histological type 
of the tumor and grade of differentiation. Tumor status and lymph node 
involvement status, as per the TNM staging were analyzed and noted in the master 
chart.     
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HAEMATOXYLIN AND EOSIN STAINING 
REAGENTS REQUIRED:  
1. Harris haematoxylin 
2. Eosin 
PROCEDURE:[53] 
1. Deparafinisation: done with xylene 
2. Hydration: hydration is done through subjecting the sections to immersion in 
graded alcohols followed by bringing into water. 
3. Haematoxylin staining: sections were stained with harris hematoxylin stain for 
10 minutes. 
4. Wash the haematoxylin stained slide in running tap water until sections become 
blue ( 5 minutes) 
5. Differentiation: done with 1% acid alcohol which is a mixture of 1% 
hydrochloric acid in 70% alcohol -  10 seconds 
6. Wash with tap water for 10 minutes 
7. Bluing by immersing the slide in ammonia water followed by washing in tap 
water for 5 minutes. 
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8. Eosin staining: stain in eosin for 10 – 15 minutes. 
9. Wash the stained slide in running tap water for 3 minutes 
10. Dehydration through graded alcohols 
11. Clearing 
12. Mounting. 
After haematoxylin and eosin staining, the slides were reviewed once again for 
adequacy and sections are taken from the respective blocks on a poly-l-lysine 
coated slide for immunohistochemical staining. 
                      IMMUNO HISTOCHEMICAL STAINING 
 Tissue blocks of normal colon sent for non – neoplastic lesions were taken as 
controls. The blocks were then cut to 5µ thick sections and taken on a Poly-L-
lysine coated slide to serve as positive control for MLH1 and MSH2 antibody. 
 Immunohistochemistry for detection of expression of MLH1 and MSH2 was 
performed using the supersensitive HRP-polymer detection system with the 
appropriate control. The procedure executed is described below:[54] 
 ANTIBODIES USED:1]  MLH 1( novocastra  , clone ES05) 
                                      2]  MSH 2 (novocastra , clone 25D12) 
47 
 
PRINCIPLE OF THE TEST:  In an immunohistochemical reaction, the specific 
antigen present in the cells and tissues was detected in a two stage process that 
includes: 
1) The binding of the primary antibody to its specific epitope in the tissues. 
2) Detection of this primary bound antibody using a dextran polymer bound 
secondary antibody in a calorimetric reaction involving a chromogen. 
In this method, primary antibody to the specific antigen is first added and is then 
followed by the addition of a dextran polymer linked to multiple conjugated 
secondary antibodies and horse raddish peroxidase enzyme. This multiple 
secondary antibodies bound to the primary antibody and the signal is amplified by 
the use of a suitable chromogen 3, 3’diaminobenzidine tetra hydrochloride (DAB) 
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Fig 1: Principle of Immunohistochemistry 
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Antigen retrieval:[54] 
This is a process to unmask the epitopes of the specific antigens that are masked by 
cross linking action of formalin during routine processing. There are various 
methods for antigen retrieval. The methods include, 
1) Pressure cooker method 
2) Microwave method 
3) Proteolytic digestion method 
Of the above, the pressure cooker method is used for the present study. Here, the 
tissue is exposed to the additive effects of both heat and pressure thereby bringing 
out the full antigenicity. After dewaxing and hydrating in graded alcohols, the 
slides were subjected to antigen retrieval in a pressure cooker for 10 minutes with 
EDTA buffer at pH 9. 
 
REAGENTS USED: 
 EDTA buffer at pH 9. [ ethylene diamine tetra acetic acid] 
    3% hydrogen peroxide ( H2O2) in distilled water - To block endogenous 
peroxidase activity in order to prevent nonspecific background staining 
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  0.01M Phosphate buffered saline (PBS) with a pH value of 7.6. It was 
prepared by dissolving the following substances in 1000 ml of distilled 
water. 
1. Na2HPO4 Dibasic sodium phosphate, anhydrate              17.5g 
2. KH2PO4 Monobasic potassium phosphate, anhydrous     2.5g  
3. NaCl Sodium chloride                                                            17.0g  
 Blocking reagent- casein in PBS with 15mM sodium azide. This was used to 
block non specific protein binding. 
 Primary antibodies against MLH1 and MSH2 antigen. As the antigens were 
in a concentrated form, they are diluted as specified in the user manual  as 
follows, before using 
1. MLH 1 antibody  is diluted with PBS in a ratio of 1:100 
2. MSH2 antibody is diluted with PBS in a ratio of 1:50 
 Poly HRP reagent- anti-mouse and anti-rabbit IgG complex linked to Horse 
radish peroxidase enzyme. 
 DAB (3, 3’Diamino Benzidine tetra hydrochloride) - Chromogen. 
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       It offers great sensitivity as an HRP calorimetric chromogen and provides 
insoluble permanent coarse brown precipitate. 
 Harris hematoxylin as counter stain. 
 DPX (Distrene dibutyl phthalate Xylene) - Mountant. 
 
PROCEDURE: 
1.  Immunohistochemical Staining with the two specific antibodies were done as 
follows         
• Slides were dewaxed . 
• Dewaxed slides were hydrated using graded alcohol. 
• Antigen retrieval: using EDTA buffer at pH 9.0 in a pressure cooker 
for 10 minutes. 
• Fast cooling under tap water. 
• Washed in PBS buffer at pH 7.6 for 5 minutes 
• After wiping off excess PBS buffer the slides were immersed in 0.3% 
H2O2 for 20 minutes to block endogenous peroxidase activity. 
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•  Washed in PBS buffer thrice,5 minutes each 
•  Slides were incubated in blocking solution for 10 minutes to block 
non-specific protein binding. 
•  Washed in PBS buffer thrice , each 5 minutes. 
•  Slides were incubated with diluted MLH 1 primary antibody for 1 Hr. 
•  To enhance the signal intensity, the sections were put in 
superenhancer for 30 minutes. 
•  Washed in PBS buffer thrice, each for 5 minutes. 
•  Horse radish peroxidase polymer reagent was added to the slide and 
incubated for 30 minutes. 
•  Washed in PBS buffer thrice, each for 5 minutes. 
• Chromogen Diamino Benzidine (DAB) was applied for 8 minutes. 
•  Washed in PBS buffer thrice, each 5 minutes. 
•  Sections were counter stained with Harris hematoxylin for 1 minute. 
•  Washed in tap water. 
• Sections were cleared in Xylene and mounted with DPX mountant. 
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The same procedure is repeated in another section from the same block using the 
second primary antibody MSH2. 
 
The stained sections were screened to analyze the expression of the two antigens, 
MLH 1 and MSH2. Apart from the control sections taken from the specimen sent 
for non-neoplastic lesion, the cells in the crypt epithelium and lymphocytes in the 
normal mucosa of the respective sections were also be used as positive control. 
The presence of these two antigens are expressed as brown colour nuclear staining. 
 
Slides were considered positive when they show a brisk nuclear positivity. Less 
than 5% of cells showing positivity were considered negative.[44] 
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  RESULTS 
  
There were 40 cases of colorectal carcinoma, of these 21 cases (52%) were males 
and 19 (47.5%) were females (Graph 1). Male to female ratio was 1.1: 1. The age 
range was between 33 and 85 years with a mean age of  58.9  years.  Maximum 
number of cases were between the age group of 41 to 80 years (Table4 & Graph2).  
The youngest patient was a 33 year old female.  
Table 4: Age distribution of the cases 
 
 
 
 
 
 
 
 
 
 
 
                                                     
 
         Age  
(years) 
No of 
cases 
No of males No of females 
             30-40       04   00    04 
             41-50       09   06   03 
             51-60       08   03   05 
             61-70       08   06   02 
            71-80       09   05   04 
            81-90       02   01   01 
         TOTAL       40   21   (52%)   19 ( 47.5%) 
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Graph 1: Gender distribution of cases 
                         
   
      
 Graph 2: Age distribution of cases 
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A high proportion of the tumors were located on the distal colon.  Out of 40 cases, 
15 cases had  tumor proximal to splenic flexure and 25 had tumor distal to splenic 
flexure.  Maximum number of cases (12/40) were seen in rectum(30%), followed 
by sigmoid colon (9/40).  (Table 5)    
TABLE 5: Site of tumors 
                     
 
 
 
       
 
 
The sizes of the tumors were ranging from 1.0 cm to 8.0 cm in greater dimension. 
20 cases were 3.0 to 6.0 cm in size.  9 cases were less than 3.0 cm and another 9 
cases were more than 6.0 cm in size. Majority of the tumors (32 cases, 80%) were 
conventional adenocarcinoma, 6 cases (15%) were mucinous adenocarcinoma and 
2 cases (5%) were signet ring cell carcinoma. (Table 6) 
                      Site 
 
           No of cases 
              Caecum 
 
             04 (10%) 
             Ascending   colon 
 
             04 (10%) 
             Transverse  colon 
 
             07 (17.5%) 
             Descending  colon 
 
             03 (7.5%) 
             Sigmoid colon 
 
             10 (25%) 
             Rectum 
 
             12 (30%) 
57 
 
 
TABLE 6: Histological type of the tumors 
       Histological type            No of cases  
       Adenocarcinoma                32   (80%) 
       Mucinous carcinoma               06   (15%) 
       Signet ring cell carcinoma               02   (5%) 
       Total                40 cases 
 
 
 
 
Histopathologically, the tumors were graded into well differentiated(fig 2), 
moderately differentiated(fig 3) and poorly differentiated. The mucinous(fig4) and 
signet ring cell carcinomas(fig 5) were also considered as poorly differentiated. 
Majority of them (27 cases, 67%) were moderately differentiated. 9 cases (22.5%) 
including the other variants like mucinous and signet ring cell carcinomas were 
poorly differentiated. (Table 7, graph 3 and graph 4) 
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Table  7: Degree of differentiation of tumors 
Histopathological grade   No of cases 
Well  differentiated 04   (10%) 
Moderately  differentiated 27   (67.5%) 
Poorly  differentiated  09   (22.5%) 
Total 40 cases 
  
 
                                Graph 3 : Histological type of tumors 
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                              Graph 4: Degree of differentiation of tumors 
      
 
   
Majority of the cases (70%) were in stage 3 and 25% of cases were in T1 stage. 
Lymph node metastases were seen in eleven cases. (table 8&9) 
 
 
 
 
 
60 
 
 
Table  8:  ‘T’ status (stage) of tumors 
         
           Tumor stage (T) 
  
                     No of cases 
                     T0                           00 
                     T1                                     01(2.5%) 
                     T2                                     10 (25%) 
                     T3                                     28(70%) 
                     T4                                     01(2.5%) 
                    Total                                    40 cases 
 
 
Table  9: ‘N’ status (lymph node involvement) of tumors 
      
       Lymph node  involvement 
                    
                       No of cases 
                            N0                          29(73%) 
                            N1                          8(20%) 
                            N2                          3(7%) 
                           Total                         40 cases 
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IMMUNOHISTOCHEMICAL DETECTION OF MMR 
PROTEINS             
 
Of the 40 cases, 12 (30%) patients had lack of expression of MSH2 protein, 4 
(10%) patients had lack of both MLH1 and MSH2 protein while the remaining 24 
cases (60%) showed both MLH1 and MSH2 positivity. (Table 10 , Graph 5) 
Table 10: Lack of MMR protien expression in the study population. 
 
    Lack of MLH1     Lack of MSH2  Lack of MLH1 &   
                    MSH2 
Normal MLH1 
and MSH2 
expression 
 
 
0   
 
   12 (30%) 
 
 
    4 (10%) 
 
 24 (60%) 
 
Out 40 cases, 16 (40%) cases showed lack of expression of either MSH2 or both 
MLH1 and MSH2. There were no cases with lack of  only MLH1 expression.  
Among these 16 cases there was equal distribution of males and females. (Table 
11, Graph 6). 
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Table 11: Gender distribution in cases showing MMR protein loss 
 
Sex  
 
 
 
Total 
Total no 
cases lacking 
MLH1/MSH2 
 
Lack of 
MLH1 
   
Lack of 
MSH2 
 
Lack of MLH1 
& MSH2 
 
Males  
 
 
21 
 
         8 
 
         0 
   
       7 
(33%) 
 
           1 (5%) 
 
Females  
 
 
      19 
 
          8 
  
         0 
 
      5 
(26%) 
 
           3 (16%) 
                                                           
                                                           
            Graph 5: Lack of MMR protien expression in the study population. 
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  Graph 6 : Gender distribution in cases showing MMR protein loss 
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Table 12: Age distribution in cases showing lack of MMR protein expression 
 
 
Age (years) No of cases Lack of 
MLH1  
Lack of 
MSH2  
Lack of 
MLH1 and 
MSH2 
30-40    04   00    00    01 (25%) 
41-50    09    00    04 (44%)    00 
51-60    08   00    02 (25%)    00 
61-70    08   00   00    01 (12.5%) 
71-80    09   00    05 (55.5%)    02 (22%) 
81-90    02   00    01 (50%)    00 
Total 
 
   40   00    12    04 
 
 
Out of 16 cases which showed loss of mismatch repair proteins, about half (50%) 
of the case where in their 7th decade , implying that in our study population , 
elderly persons featured an increase in lack of expression of mismatch repair 
proteins. (Table 12) 
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Table 13: Size of tumor in correlation with MMR protein loss 
 
 
The sizes of the tumors were ranging from 1cm to 9 cm in greater dimension. 
Majority of the cases (29/40) were between 3cm and 6 cm and 5 cases were less 
than 3cm in size. Out of  5 cases with size less than 3 cm,  3 cases (60%) showed 
isolated negative staining for MSH2 protein. Lack of expression of both MSH2 and 
MLH1 was common among tumors measuring > 6 cm in size (Table 13).  
In our present study 32/ 40 cases were conventional adenocarcinomas and among 
these only 10 cases showed alteration in expression of MLH1 / MSH2 protein. 
Remaining 22 cases had normal expression of MLH1/ MSH2 protein(fig 6 and fig 
7) (Table 14) 
 
 
             
           Size 
 
 
 
Total 
 
 
Lack of 
MLH1 
   
 
Lack of 
MSH2 
 
 
Lack of MLH1 
& MSH2 
 
  Less than 3 cm 
 
 
       5 
  
0 
     
     3(60%) 
 
            0 
 
  3< size <6 cm 
 
       
      29 
 
0 
     
     8(25%) 
 
            2(7%) 
 
       > 6cm 
 
        
      6 
 
0 
     
     1(16.7%) 
 
            2(33%) 
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Table 14: Histological type of tumor in correlation with lack of expression of 
MMR proteins. 
 
 
When lack of expression of MLH1 and MSH2 was correlated with tumor grade it 
was found to be associated with higher grade.  Of the 16 cases which showed 
MLH1 / MSH2 alteration or both, 7 cases were moderately differentiated and 
remaining 7 cases were poorly differentiated (fig 8 and fig 9) . 
 
  
Histological type  Total  Lack of MLH1 Lack of MSH2 Lack of MLH1 
& MSH2 
Adenocarcinoma 
(conventional) 
 
    32 
         
            0 
           
       6 (19%) 
             
       4 (12.5%) 
Mucinous 
adenocarcinoma 
 
     6 
        
           0 
           
       5 (83%) 
           
       0 
Signet ring cell 
carcinoma   
 
    2 
        
          0 
          
        1 (50%) 
            
       0 
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In our study mucinous adenocarcinoma and signet ring cell carcinoma(fig 10 and 
fig 11)were considered as poorly differentiated and 83% of mucinous 
adenocarcinomas  (5/6) showed lack of MSH2 expression. (Table 15) 
 
Table: 15 : Grade of tumor in correlation with MMR protein loss 
 
Tumor  
Grade 
TOTAL Lack of 
MLH1 
Lack of 
MSH2 
Lack of MLH1 & 
MSH2 
Well  
differentiated  
 
 
     4 
 
         0 
 
      2 (50%)  
 
           0 
Moderately 
differentiated 
 
 
   27 
  
        0 
 
      4 (15%) 
               
         3(11%) 
Poorly  
Differentiated 
 
 
   9 
 
       0 
 
      6 (67%) 
 
        1(11%) 
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While correlating lack of MLH1 and MSH2 expression with site of occurrence, it 
was found to be associated mostly with rectal origin (77%) and it showed isolated 
loss of MSH2 in 33% and remaining 44% showed alteration in both MLH1 and 
MSH2 expression. (Table 16) 
 Table 16: Site of tumor in correlation with MMR protein loss 
Site Total Lack of 
MLH1 
Lack of 
MSH2 
Lack of MLH1 and 
MSH2  
 
Caecum 4 0 3(75%) 
 
0 
 
 
Asc. colon 4 0 1(25%) 
 
1(25%) 
 
 
Tr. colon 7 0 2(28%) 
 
1(14%) 
 
 
Desc. colon 3 0 1 (33%) 
 
0 
 
 
Sigmoid 10 
 
0 2 (20%) 
 
0 
 
 
Rectum  12 0 3 (25%) 
 
2(16%) 
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Loss of expression was more common on tumors on proximal colon compared to  
distal colon. (Graph 7) 
                                            
                  Graph 7 : Site of tumor in correlation with MMR protein loss 
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Of the 16 cases with alteration in MLH1 and MSH2, 11 cases were in T3 stage 
showing that the loss of expression was associated with higher stage. Among the 
40 cases in study group, 28 were of T3 grade among which 11 showed lack of 
mismatch repair proteins. One case was in stage T4, which also showed lack of 
MLH1 and MSH2. (Table 17, graph 8) 
Table 17: Stage of tumor in correlation with lack of MMR protein 
 
 
 
   Stage of 
the tumor 
 
    Total     
       no     
 
 Lack of 
mlh1 
 
Lack of 
msh2 
 
Lack of mlh1 and msh2 
 
 
      
    To 
 
       0 
  
     0 
 
       0 
             
               0 
 
 
     
    T1 
 
      1 
 
     0 
 
       0 
             
              0 
 
 
     
    T2 
 
     10 
 
     0 
 
  3(30%) 
            
              1(10%)  
 
 
    
    T3 
 
      28 
 
     0 
 
  9(32%) 
           
             2(7%) 
  
 
     
   T4 
 
      1 
 
    0 
    
 0 
         
            1(100%) 
 
 
71 
 
                  Graph 8: Stage of tumor in correlation with MMR protein loss 
 
 
In our study expression of MLH1 and MSH2 did not have significant correlation 
with the lymph node involvement. Of the 40 cases, 29 cases were in N0 stage, 8 
cases were in N1 and 3cases were in N2 stage. All the four cases with lack of both 
MLH1 and MSH2 were with no nodal metastases (N0). Table 18 and graph 9 
depicts the correlation of lymph node involvement and expression of MMR 
proteins. 
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Table 18: Lymph node involvement by the tumor in correlation with MMR  
protein loss 
 
 
Graph 9: Lymph node involvement by the tumor in correlation with lack of 
MMR protein 
 
 
 
 
 
 
 
 
Node 
involvement 
 
Total no of 
cases 
Lack of mlh1 Lack of msh2 Lack of mlh1 
and msh2 
 
            N0 
 
       29 
 
         0 
 
     7(24%) 
 
   4(14%) 
 
 
           N1 
 
       8 
 
         0 
 
     4(50%) 
 
          0 
 
 
           N2 
 
       3 
 
        0 
 
     1(33%) 
 
          0 
 
 
0
1
2
3
4
5
6
7
N0
N1
N2
LYMPH NODE INVOLVEMENT
LACK OF MLH1
LACK OF MSH2
LACK OF MLH1 & MSH2
73 
 
                                                  STATISTICAL DATA 
Method of sampling: Systematic Random Sampling 
Research design: Descriptive study 
 The data obtained were entered in the master chart , coded and edited. The 
inferential and descriptive analysis of these data were computed using a software 
SSPS-17. The association between the variables and the lack of expression of  
MLH1 and MSH2 were determined by using chi- square test. 
Association between sex and loss of MLH1 and MSH2: 
 Table 19  - Sex & Lack of Expression Crosstabulation 
 
 
7 1 13 21
33.3% 4.8% 61.9% 100.0%
58.3% 25.0% 54.2% 52.5%
5 3 11 19
26.3% 15.8% 57.9% 100.0%
41.7% 75.0% 45.8% 47.5%
12 4 24 40
30.0% 10.0% 60.0% 100.0%
100.0% 100.0% 100.0% 100.0%
Count
% within Sex 
% within Lack 
of Expression
Count
% within Sex 
% within Lack 
of Expression
Count
% within Sex 
% within Lack 
of Expression
Male
Female 
Sex 
Total 
MSH2
MLH1 and 
MSH2
Normal MLH1
and MSH2 
Lack of Expression
Total 
74 
 
In the previous table the chi- square value 1.40 for the association  between gender 
and lack of expression of MLH1 and MSH2 is not significant (p =0.496) revealing 
that there is no association between age and the MMR protein loss. (Table 19) 
Association between age and MMR protein loss: 
           Table 20:  Age in Years & Lack of Expression Crosstabulation 
 
 
0 1 3 4
.0% 25.0% 75.0% 100.0% 
.0% 25.0% 12.5% 10.0%
4 0 5 9
44.4% .0% 55.6% 100.0% 
33.3% .0% 20.8% 22.5%
2 0 6 8
25.0% .0% 75.0% 100.0% 
16.7% .0% 25.0% 20.0%
0 1 7 8
.0% 12.5% 87.5% 100.0% 
.0% 25.0% 29.2% 20.0%
5 2 2 9
55.6% 22.2% 22.2% 100.0% 
41.7% 50.0% 8.3% 22.5%
1 0 1 2
50.0% .0% 50.0% 100.0% 
8.3% .0% 4.2% 5.0%
12 4 24 40
30.0% 10.0% 60.0% 100.0% 
100.0% 100.0% 100.0% 100.0% 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Count 
% within Years 
% within Lack
of Expression 
Less than 40 years
41 - 50 years
51 - 60 years
61 - 70 years
71 - 80 years
Above 81 years
Years 
Total 
MSH2 
MLH1 and
MSH2 
Normal MLH1
and MSH2 
Lack of Expression
Total
75 
 
In the previous table the chi- square value 14.375 for the association  between age 
and lack of expression of MLH1 and MSH2 is not significant (p =0.157) revealing 
that there is no association between age and the MMR protein loss. (Table 20) 
 Association between size of the tumour and MMR protein loss: 
                                  Table 21 : Size & Lack of Expression Crosstabulation 
 
From the above table there found to be no association between the tumor size and 
lack of MMR protein expression , the chi square value being 6.53 and p=0.162. 
(Table 21) 
 
 
3 0 2 5 
60.0% .0% 40.0% 100.0%
25.0% .0% 8.3% 12.5%
8 2 19 29
27.6% 6.9% 65.5% 100.0%
66.7% 50.0% 79.2% 72.5%
1 2 3 6 
16.7% 33.3% 50.0% 100.0%
8.3% 50.0% 12.5% 15.0%
12 4 24 40
30.0% 10.0% 60.0% 100.0%
100.0% 100.0% 100.0% 100.0%
Count 
% within Size
% within Lack
of Expression
Count 
% within Size
% within Lack
of Expression
Count 
% within Size
% within Lack
of Expression
Count 
% within Size
% within Lack
of Expression
Less than 3 cm 
Between 3 - 6 cm 
Above 3 cm 
Size
Total
MSH2
MLH1 and
MSH2
Normal MLH1 
and MSH2
Lack of Expression
Total
76 
 
 
Association between histological type and lack of MMR expression: 
The chi- square value for the association between these two variables is 10.625 and 
is significant(p<0.05) revealing a strong association between the histological type 
of tumor and lack of expression of the MMR proteins.(Table 22) 
 
               Table 22: Histological type  & Lack of Expression Crosstabulation 
 
 
 
6 4 22 32
18.8% 12.5% 68.8% 100.0% 
50.0% 100.0% 91.7% 80.0%
5 0 1 6
83.3% .0% 16.7% 100.0% 
41.7% .0% 4.2% 15.0%
1 0 1 2
50.0% .0% 50.0% 100.0% 
8.3% .0% 4.2% 5.0%
12 4 24 40
30.0% 10.0% 60.0% 100.0% 
100.0% 100.0% 100.0% 100.0% 
Count
% within type
% within Lack of
Expression 
Count
% within type
% within Lack of
Expression 
Count
% within type
% within Lack of
Expression 
Count
% within type
% within Lack of
Expression 
Adenocarcinoma 
(conventional)
Mucinous
Adenocarcinoma
Signet Ring cell
Carcinoma
Histological
type 
Total 
MSH2
MLH1 and 
MSH2
Normal MLH1 
and MSH2
Lack of Expression
Total
77 
 
 
Association between degree of differentiation and MMR protein loss: 
 
 Table 23:  Differentiation of Tumor & Lack of Expression Crosstabulation 
 
 
 
In the above table the chi- square value 10.185 for the association  between degree 
of differentiation and lack of expression of MLH1 and MSH2 is not significant (p 
<0.05) revealing that there is an association between degree of differentiation and 
the MMR protein loss.(Table 23) 
 
 
2 0 2 4 
50.0% .0% 50.0% 100.0%
16.7% .0% 8.3% 10.0%
4 3 20 27
14.8% 11.1% 74.1% 100.0%
33.3% 75.0% 83.3% 67.5%
6 1 2 9 
66.7% 11.1% 22.2% 100.0%
50.0% 25.0% 8.3% 22.5%
12 4 24 40
30.0% 10.0% 60.0% 100.0%
100.0% 100.0% 100.0% 100.0%
Count 
% within Tumor 
% within Lack
of Expression
Count 
% within Tumor 
% within Lack
of Expression
Count 
% within Tumor 
% within Lack
of Expression
Count 
% within Tumor 
% within Lack
of Expression
Well Differentiated
Moderately Differentiated 
Poorly Differentiated 
Tumor
Total 
MSH2
MLH1 and
MSH2
Normal MLH1
and MSH2
Lack of Expression
Total 
78 
 
Association between site and lack of MMR proteins: 
                          Table 24 : Site & Lack of Expression Crosstabulation 
 
 
In the above table the chi- square value 8.03for the association  between site of 
tumor and lack of expression of MLH1 and MSH2 is not significant (p =0.626) 
 
3 0 1 4
75.0% .0% 25.0% 100.0% 
25.0% .0% 4.2% 10.0%
1 1 2 4
25.0% 25.0% 50.0% 100.0% 
8.3% 25.0% 8.3% 10.0%
2 1 4 7
28.6% 14.3% 57.1% 100.0% 
16.7% 25.0% 16.7% 17.5%
1 0 2 3
33.3% .0% 66.7% 100.0% 
8.3% .0% 8.3% 7.5%
2 0 8 10 
20.0% .0% 80.0% 100.0% 
16.7% .0% 33.3% 25.0%
3 2 7 12 
25.0% 16.7% 58.3% 100.0% 
25.0% 50.0% 29.2% 30.0%
12 4 24 40 
30.0% 10.0% 60.0% 100.0% 
100.0% 100.0% 100.0% 100.0% 
Count
% within Site
% within Lack
of Expression
Count
% within Site
% within Lack
of Expression
Count
% within Site
% within Lack
of Expression
Count
% within Site
% within Lack
of Expression 
Count 
% within Site 
% within Lack
of Expression 
Count 
% within Site 
% within Lack
of Expression 
Count 
% within Site 
% within Lack
of Expression 
Caecum 
Asc. colon 
Tr. colon
Desc. colon
Sigmoid 
Rectum 
Site 
Total
MSH2 
MLH1 and 
MSH2 
Normal MLH1
and MSH2 
Lack of Expression
Total
79 
 
revealing that there is no association between site and the MMR protein loss. 
(Table 24) 
Association between tumor stage and lack of MMR proteins: 
               Table 25: Stage of Tumor&Lack of Expression Crosstabulation 
 
 
From the above table there found to be no association between the tumor stage and 
lack of MMR protein expression , the chi square value being  9.94 and p=0.127. 
(Table 25) 
 
0 0 1 1
.0% .0% 100.0% 100.0%
.0% .0% 4.2% 2.5%
3 1 6 10 
30.0% 10.0% 60.0% 100.0%
25.0% 25.0% 25.0% 25.0%
9 2 17 28 
32.1% 7.1% 60.7% 100.0%
75.0% 50.0% 70.8% 70.0%
0 1 0 1
.0% 100.0% .0% 100.0%
.0% 25.0% .0% 2.5%
12 4 24 40 
30.0% 10.0% 60.0% 100.0%
100.0% 100.0% 100.0% 100.0%
Count
% within Stage of Tumor
% within Lack of
Expression
Count
% within Stage of Tumor
% within Lack of
Expression
Count
% within Stage of Tumor
% within Lack of
Expression
Count
% within Stage of Tumor
% within Lack of
Expression
Count
% within Stage of Tumor
% within Lack of
Expression
T1
T2
T3
T4
Stage of 
Tumor
Total
MSH2 
MLH1 and 
MSH2 
Normal MLH1
and MSH2 
Lack of Expression
Total
80 
 
Association between the nodal involvement and MMR protein loss: 
 
              Table 26: Node involvement & Lack of Expression Crosstabulation 
 
 
 
In the above table the chi- square value 3.10 for the association  between lymph 
node involvement and lack of expression of MLH1 and MSH2 is not significant (p 
=0.541) revealing that there is no association between lymph node metastases and 
the MMR protein loss. (Table 26). 
 
7 4 18 29
24.1% 13.8% 62.1% 100.0% 
58.3% 100.0% 75.0% 72.5%
4 0 4 8 
50.0% .0% 50.0% 100.0% 
33.3% .0% 16.7% 20.0%
1 0 2 3 
33.3% .0% 66.7% 100.0% 
8.3% .0% 8.3% 7.5% 
12 4 24 40
30.0% 10.0% 60.0% 100.0% 
100.0% 100.0% 100.0% 100.0% 
Count
% within Node
involvement
% within Lack
of Expression
Count
% within Node
involvement
% within Lack
of Expression
Count
% within Node
involvement
% within Lack
of Expression
Count
% within Node
involvement
% within Lack
of Expression
N0
N1
N2
Node involvement
Total
MSH2 
MLH1 and
MSH2 
Normal MLH1
and MSH2
Lack of Expression
Total
81 
 
                            DISCUSSION 
Colorectal cancer is the third most common type of malignancy in western 
countries. 15% of sporadic cases are due to MSI. In MSI, there are frame shift 
mutations and base pair substitutions in microsatellites. Microsatellites are 
repetitive genetic loci with 1 to 5 base pairs repeated 15 to 30 times. These 
mutations in microsatellites occur mainly during DNA replication and are normally 
controlled by the DNA mismatch repair genes such as MLH1, MSH2, MSH6, 
PMS2 and MSH3. MLH1 recruits its binding partner PMS2 to the site of DNA 
injury, so if the expression of MLH1 is lost then PMS2 will also be lost. Similarly, 
when MSH2 is lost, MSH6 will be lost.  Several studies have reported that defect 
in MMR genes forms the basis for MSI.  MSI is seen in all cases of HNPCC and a 
subset of sporadic colorectal carcinoma. [55]  Mutations of MLH1 and MSH2 are 
more common and they occur in exon 16 and exon 12 of the genes respectively. It 
is important to screen all colorectal carcinomas for MSI, regardless of patient’s age 
or family history. This helps in detecting sporadic cases with MMR protein defect 
and also potential cases of Lynch syndrome.   
 
Sporadic tumors with microsatellite instability have a better prognosis when 
compared to microsatellite stable tumors (MSS). MSI tumors may respond less 
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favorably to 5- fluorouracil- based chemotherapy. Therefore, the knowledge of 
MSI status may pave the way to assess the prognosis and for therapy.  
 
The screening can be done either by molecular methods or by 
immunohistochemical marker study for MSI and MMR protein. Molecular method 
is considered to be the gold standard for diagnosing mismatch repair genes but 
several recent studies have shown > 95% specificity of immunohistochemical 
analysis for mismatch repair genes.  
 
The present study is an attempt to determine the frequency of loss of mismatch 
repair protein (MLH1 and MSH2) expression by immunohistochemical analysis 
and to study its correlation with various clinicopathologic characteristics. IHC 
determination of MLHI and MSH2 is becoming a more popular technique as it can 
define the MMR status in paraffin embedded tissue.  Immunohistochemical 
analysis is less expensive and less time consuming when compared to molecular 
analysis. It is less labour intensive and is readily available to most diagnostic 
anatomic pathology laboratories while molecular testing is not. Other advantage 
with IHC is the availability of tissues to evaluate histopathological features of the 
tumors.[56]    
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We observed that in our study population there is 10% cases(4/40) lacked the 
expression of both the mismatch repair proteins. It was also observed that isolated 
loss of MSH2 was seen in 30% (12/40) cases. This is significantly higher when 
compared to the study done by Vijay pandey et al which quotes an incidence of 
17% in an Indian cohort. Our literature search using google search engine showed 
only a few similar studies done in the Indian subcontinent. [39] 
 
 In the present study we also correlated various clinico-pathological features with 
MMR expression. Clinicopathological features studied include age of the patient, 
sex of the patient , location of the tumor, histological type, grade, stage of the 
tumor (T-stage) and lymph node involvement. The purpose of this was to establish 
any association between MMR expression and these variables. 
 In our study ,  the study population encompassed patients with age range between 
33 and 85 years with a mean age of 58.9 years. 13 cases were below 50 years of 
age and the remaining 27 cases were above 50 years of age. The male to female 
ratio was 1.1:1 (21:19). Majority of the tumors were located in the distal colon, 
mostly from rectum which was in agreement with the previous study. [39] The sizes 
of the tumors varied from 1.0 cm to 8.0 cm in greatest dimension. Out of 40 cases, 
32 were conventional adenocarcinomas, 6 were mucinous adenocarcinomas and 2 
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cases were signet ring cell type carcinomas. With respect to differentiation, 4 cases 
were well differentiated, 27 cases were moderately differentiated and 9 cases were 
poorly differentiated , including mucinous carcinomas and signet ring cell 
carcinomas. Lymph node metastases were noted in eleven cases. 
            While correlating the loss of expression of MLH1 and MSH2 with various 
clinicopathologic characters , we found that lack of expression of MSH2 and both 
of MLH1 and MSH2 were more often seen in females (46%) when compared to 
males(38%), similar to the study by K.Ohrling. They had stated that there is a 
relationship between the lack of MMR gene and gender.[56] However in our 
statistical analysis, we found that there is no significant (p=0.496)  association 
between these two variables as evolved by a chi- square value of 1.40 . 
    In our study MMR defective tumors developed in the age group between 35 
years and 85 years with a more frequent incidence in the 7th decade. This was in 
correlation with the study of  Rodrigo jover et al [55] where the mean age at 
diagnosis was high (70.5 yrs). Yet another study by Valerie Rigau  showed that 
loss of MLH1 expression was frequent in elderly women.  This proves that 
advanced age at the time of diagnosis does not rule out the possibility of hereditary 
non-polyposis colorectal carcinoma (HNPCC). [57] In our statistical analysis, the 
chi- square value 14.375 for the association between age and lack of expression of 
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MLH1 and MSH2 is not significant (p =0.157) revealing that there is no 
association between age and the MMR protein loss. 
 
In the present study majority of the tumors (29/40) were between 3and 6 cm in size 
and 5 cases were less than 3cm in size. Of the 5 cases which are smaller than 3 cm 
in size, 3 cases (60%) showed isolated negative staining for MSH2 protein. Of the 
six cases larger than 6 cm in size only one case showed lack of MSH2 protein and 
two cases showed alteration in expression of both the proteins. This finding was 
different with previously reported studies which states that MSI tumors more often 
display larger size.[49] But in our study statistical analysis did not show any 
association between the tumor size and lack of MMR protein expression, the chi 
square value being 6.53 and  p=0.162. 
       Tumors occurring in the caecum, ascending colon and transverse colon were 
classified as proximal colorectal carcinomas and tumors in the descending colon, 
sigmoid colon and rectum were classified as distal colorectal carcinomas. In our 
study, lack of  MLH1 and MSH2 was more common on tumors on proximal colon 
compared to distal colon. In the present study, abnormality of MMR protein 
expression was observed in 53.3% of the proximal colorectal carcinomas when 
compared to only 32% of distal colorectal carcinomas. Few studies correlating 
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with these findings have been recorded in literature. The various studies suggested 
that early onset microsatellite instable tumors were located in proximal colon and 
mostly showed a poorly differentiated grade. Eventhough the lack of expression of 
MMR protein was more among the tumors on proximal colon, statistically it was 
not significant.[58,59] The chi- square value of 8.03for the association between site of 
tumor and lack of expression of MLH1 and MSH2 is not significant (p =0.626) 
revealing that there is no association between site and the MMR protein loss. 
 
With regard to the histological type of the tumor, lack of MSH2 protein was more 
associated with mucinous adenocarcinoma (83%) and signet ring cell carcinoma 
(50%) compared to conventional adenocarcinoma. In this series, only19% of 
conventional adenocarcinoma  showed  loss of expression of MSH2  and 12.5% 
showed lack of expression both MLH1 and MSH2 protein. This was in agreement 
with a previous study done by Roberta Gafa et al [60] , where it was found that in a 
series of 216 cases, MSI tumors were found to be closely related to poorly 
differentiated tumors and mostly in mucinous adenocarcinoma.This would suggest 
a correlation between histologic type of the tumor and MMR protein expression. 
Statiscal analysis showed that there is a strong association between the histological 
type and MMR protein loss.The chi- square value for the association between these 
two variables was found to be 10.625 and is significant (p<0.05).  
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             MMR protein expression was also found to be closely related to grade of 
the tumor.  Of the 9cases of poorly differentiated adenocarcinomas, 6 cases 
showed loss of expression of MSH2 protein and one case showed lack of both 
MLH1 and MSH2 protein. The association between degree of differentiation and 
expression of MLH1 and MSH2 was found to be statistically significant. The chi- 
square value for these two variables is 10.625 and is significant (p<0.05) revealing 
a strong association. Most of the well differentiated tumors were positive for MMR 
protein, only 26% of cases showed deficient MMR protein.  
           A Previously reported study showed poorly differentiated tumors was 
associated with loss of MLH1 and the mucinous and medullary carcinomas were 
more frequently MLH1 negative and MSH2 positive.[57]  Our present study 
however has contradicted these observations. In our study, poorly differentiated 
tumors including the mucinous adenocarcinomas were more often MSH2 negative. 
Adrian Gologan did a study to review the performance of the revised Bethesda 
guidelines. They had also studied various histological features and found that all 
the MSI cases were in more advanced stages (T2 and T3).[43] In our present study 
there was only one case each in stage T1 and stage T4 and were no cases in stage 
T0. One case in stage T1 was positive for mismatch repair protein and the other 
case in stage T4 was mismatch repair protein negative. Tumors in stage 2 and 3 
showed lack of expression of MMR protein 40% and 39% respectively. 
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Statistically also there was no association between the tumor stage and lack of 
MMR protein expression, the chi square value being 9.94 and p=0.127. 
           We were unable to establish a statistical correlation between MLH1 and 
MSH2 expression and lymph node involvement.  The chi- square value 3.10 for the 
association between lymph node involvement and lack of expression of MLH1 and 
MSH2 was not significant (p =0.541). In our study 1/ 3 cases in N2 stage and 4/8 
cases in N1 stage showed lack of MSH2 protein. One of the reasons could have 
been the less number of cases with lymph node metastasis.  However no 
correlation between lymph node involvement and lack of MMR protein has been 
recorded in literature.  
Screening for MSI helps in detecting sporadic cases with MMR protein defect and 
also potential cases of Lynch syndrome. In the present study 40% (16/40) cases 
showed lack of  expression of either MSH2 or both MLH1 and MSH2 by 
immunohistochemical method. Among the various variables studied, only 
histological type and grade of the tumor showed statistically significant correlation 
with lack of mismatch repair protein. In colorectal carcinomas with MSI the 
common deficit proteins are MLH1 and MSH2.  However a small proportion of 
MSI colorectal tumors are due to mutations in other MMR genes like MSH6, 
PMS1 and PMS 2. Hence, addition of antibodies against these proteins is also 
recommended in screening of colorectal carcinomas with MSI.    
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    SUMMARY AND CONCLUSION 
 
  40% of the colorectal cancers studied lacked the expression of mismatch 
repair proteins (MMR) ,MLH1 and MSH2 which is significantly high 
when compared to other studies done in India. 
 Loss of MMR protein was found to occur in older age group(7th decade). 
 Among the various variables studied, only histological type and grade of 
the tumor showed statistically significant correlation. 
 MSH2 negative tumors were mostly poorly differentiated 
adenocarcinomas which included mucinous and signet ring cell 
carcinomas. 
 Immunohistochemical staining for MMR proteins can be used as a 
reliable tool to detect MSI in colorectal cancers. This will help in the 
identification of these patients whose relatives need to be screened 
periodically to prevent the occurrence of colorectal cancer in them. 
 The current study has tested only for the two common MMR proteins. 
Further studies are required to identify the occurrence of rare MMR 
proteins also. 
 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 2: Well differentiated  adenocarcinoma ( H&E, 10X) 
 
 
Fig 3: moderately differentiated adenocarcinoma (H & E, 10X) 
 
  
Fig 4: Mucinous adenocarcinoma (H &E , 10X) 
 
Fig 5: Signet ring cell carcinoma (H&E , 10X) 
 
 Fig 6: Moderately differentiated adenocarcinoma  with MLH1 nuclear 
positivity (IHC,10x). Inset shows  high power view (IHC, 40x) 
 
 
Fig 7: Moderately differentiated adenocarcinoma  with MSH2 nuclear 
positivity (IHC,10x). Inset shows  high power view (IHC, 40x) 
  
Fig 10: Signet ring cell carcinoma with MLH1 nuclear 
positivity(IHC,10X). Inset shows high power view.(IHC,40X). 
 
Fig 11: Signet ring cell carcinoma with negative MSH2 
staining.(IHC,10X). Inset shows high power view(IHC,40X)  
 Fig 8: Poorly differentiated adenocarcinoma with negative MLH1 
staining (IHC,10x). 
 
Fig 9: Poorly differentiated adenocarcinoma with negative MSH2 
staining (IHC,10x). 
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Master chart 
s.no HP No: age sex Size of 
tumor 
Site of 
tumor 
grade stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
1 S337/10 83 years male 4x3.5 cm Sigmoid 
colon 
Moderately 
differentiated 
T2 N0 Positive Positive 
2 S883/10 55 years female 6 cms 
along long 
axis 
Rectum Moderately 
differentiated 
T3 N0 Positive Positive 
3 S979/10 74 years  male 5x3 cm Transverse 
colon 
Moderately 
differentiated 
T3 N0 positive Positive 
4 S1792/10 69 years Male 6x3 cm Ascending 
colon 
Well differentiated T3 N1 positive Positive 
5 S1938/10 63 years male 6x2 cm Sigmoid 
colon 
Mucinous 
adenocarcinoma 
T3 N2 Positive Positive 
6 S1950/10 72 years  Male 5 cm along 
long axis 
Ascending 
colon 
Moderately 
differentiated 
T3 N0 Positive Positive 
7 S2358/10 52 years Female 1.3x1 cm Rectum Moderately 
differentiated 
T2 N0 Positive Positive 
 
 
s. no HP No Age Sex Size of 
tumor 
Site of 
tumor 
Grade Stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
8 S2373/10 70 years Male 3cm along 
long axis 
Caecum Signet ring cell 
caecinoma 
T3 N2 Positive Negative 
9 S2658/10 53 years Female 3x4 cm Sigmoid 
colon 
Moderately 
differentiated  
T3 N1 Positive Positive 
10 S3076/10 78 years Male 3.5 cm 
along long 
axis 
Descending 
colon 
Moderately 
differentiated 
T3 N1 Positive Negative 
11 S3185/10 59 years Male 8x4 cm Sigmoid 
colon 
Moderately 
differentiated 
T3 N1 Positive Positive 
12 S3313/10 33 years Female 3x2.8 cm Rectum Well 
differentiated 
T2 N0 Positive Positive 
13 S3792/10 35 years Female 9x3 cm Transverse 
colon 
Poorly 
differentiated 
adenocarcinoma 
T4 N0 Negative Negative 
s.no HP No Age Sex Size of 
tumor 
Site of 
tumor 
Grade Stage Lymphnode 
involvement 
MLH1 
expression 
MSH2 
14 S3817/10 76 years Male 5x4 cm Ascending 
colon 
Moderately 
differentiated 
T3 N0 Negative Negative 
15 S4301/10 44 years Male 4x4 cm Transverse 
colon 
Mucinous 
adenocarcinoma 
T3 N1 Positive Negative 
16 S4542/10 71 years Male 4 cm 
along long 
axis  
Caecum Moderately 
differentiated 
T3 N0 Positive Positive  
17 S3912/10 43 years Female 2 cm 
along long 
axis 
Sigmoid 
colon 
Moderately 
differentiated 
T3 N0 Positive Negative  
18 S2793/11 52 years Female 8 cm 
along long 
axis 
Sigmoid 
colon 
Moderately 
differentiated 
T3 N0 Positive Positive 
19 S1932/11 35 years  Female 3 cm 
along long 
axis 
Rectum Moderately 
differentiated 
T3 N0 Positive Positive 
s.no HP No  sex Size of 
tumor 
Site of 
tumor 
Grade stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
20 S45/11 78 years Female 1 cm 
stricture 
Caecum Well 
differentiated 
T2 N0 Positive Negative  
21 S646/11 55 years Female 5cm along 
long axis 
Transverse 
colon 
Moderately 
differentiated 
T2 N0 Positive Positive 
22 S2545/11 61 years Male 2x2.5 cm Sigmoid 
colon  
Moderately 
differentiated 
T1 N0 Positive Positive 
23 S2487/11 70 years Male 6x4 cm Transverse 
colon 
Moderately 
differentiated 
T2 N0 Positive Positive 
24 S332/09 70 years Male 6.5x5 cm Rectum Moderately 
differentiated 
T3 N0 Positive Negative 
25 S3209/09 49 years Male 4x3 cm Rectum Well 
differentiated 
T2 N0 Positive Negative 
s.no HP No age sex Size of 
tumor 
Site of 
tumor 
grade stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
26 S2655/09 52 years Male 4.5x3.5 
cm 
Ascending 
colon 
Mucinous 
adenocarcinoma 
T2 N0 Positive Negative  
27 S1067/09 43 years Male 4.2x4 cm Sigmoid 
colon 
Moderately 
differentiated 
T2 N0 Positive Positive 
28 S5041/09 38 years Female 3.2x3 cm rectum Moderately 
differentiated 
T3 N0 Positive Positive  
29 S400/09 42 years Male 2.5x1 cm Rectum Moderately 
differentiated 
T3 N2 Positive Positive  
30 S1427/09 50 years Male 5.5x5 cm Rectum Moderately 
differentiated 
T2 N0 Positive Positive 
31 S2766/08 43 years Female 6x5 cm Rectum Moderately 
differentiated 
T3 N1 Positive Negative 
s.no HP No age sex Size of 
tumor 
Site of 
tumor 
grade stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
32 S190/08 61 years Female 8x6.5 cm Rectum Moderately 
differentiated 
T2 N0 Negative Negative 
33 S4355/08 72 years Female 6x4.5 cm Sigmoid Mucinous 
adenocarcinoma 
T3 N0 Positive Negative 
34 S4169/08 58 years Male 6x6.5 cm Caecum Mucinous 
adenocarcinoma 
T3 N0 Positive Negative 
35 S4367/08 48 years Female 3x2 cm Rectum Moderately 
differentiated 
T3 N0 Positive Positive 
36 S1237/08 66 years Female 6x5 cm  Descending 
colon 
Moderately 
differentiated 
T3 N0 Positive Positive 
37 S1944/09 75 years Female 4x2.5 cm Rectum Moderately 
differentiated 
T3 N0 Negative Negative  
 s.no HP No age sex Size of 
tumor 
Site of 
tumor 
grade stage Lymph node 
involvement 
MLH1 
expression 
MSH2 
expression 
38 S2757/09 45 years Male 6x 4.5 cm Transverse 
colon 
Mucinous 
adenocarcinoma 
T3 N1 Positive Positive 
39 S3178/09 85 years Female 4.5x6 cm Transverse 
colon 
Signet ring cell 
carcinoma 
T3 N1 Positive  Negative 
40 S2062/10 78 years Female 3.5 cm 
along long 
axis 
Sigmoid 
colon 
Moderately 
differentiated 
T3 N0 Positive Positive  
